NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Co-Diagnostics, Inc. Common Stock (CODX) Stock Analysis

Co-Diagnostics, Inc. Common Stock (CODX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CODX

$0.64

−$0.01 (−0.82%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CODX with… →

CODX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.67
Previous Close
$0.65
Day's Range
0.61–0.67
52-Week Range
0.61–46.50
Volume
714.97K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.90
Valuation
Market Cap
$4.48M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.21
EPS (ttm)Profit attributable to each share over the last twelve months.
−26.14
Financials (FY)
Revenue (FY)
$622.49K−84.10%
Net Income (FY)
−$46.90M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.98M
1-Year Return
−93.69%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
368.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CODX closed at $0.64, −93.69% over 1 year.

Co-Diagnostics, Inc. Common Stock (CODX) has a market capitalization of $4.48M.

In fiscal 2025, CODX reported revenue of $622.49K.

CODX Stock Return by Calendar Year

Co-Diagnostics, Inc. Common Stock (CODX) return since Jul 2017: what $10,000 became

1 year
$10,000 $631
−93.69%
5 years
$10,000 $25
−99.75%
Since Jul 2017
$10,000 $37
−99.63%

If you had invested $10,000 in Co-Diagnostics, Inc. Common Stock (CODX) at the close on July 12, 2017, the earliest close on record here, it would have been worth $37 at the close on October 21, 2026: −99.63% in total, −45.35% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−87.34%
2025−77.47%
2024−43.61%
2023−47.22%
2022−71.78%
2021−3.98%
2020+939.11%
2019−39.93%
2018−43.56%
2017 (partial year)−54.56%

As of October 21, 2026.

CODX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$622.49K−$46.90M−7,533.6%
2024$3.92M−$37.64M−961.4%
2023$6.81M−$35.33M−518.7%
2022$34.22M−$14.24M−41.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$622.49K$400.11K−$31.28M−$46.90M−7,533.6%
2024$3.92M$2.92M−$40.08M−$37.64M−961.4%
2023$6.81M$2.63M−$42.71M−$35.33M−518.7%
2022$34.22M$28.74M−$11.59M−$14.24M−41.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CODX Valuation vs Medical Devices Median

Median of 145 stocks
MetricCODXMedical Devices medianvs median
P/S ratio6.212.53146% above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Co-Diagnostics, Inc. Common Stock (CODX) is capitalised at $4.48M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 115.

CODX last closed at $0.64 on October 21, 2026. That is −$0.01 (−0.82%) against the previous close. The 52-week range on file runs from $0.61 to $46.50. The latest close sits 5.77% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $622.49K. That is −84.10% against the prior fiscal year, when revenue was $3.92M. The same year closed with a net loss of $46.90M. Trailing earnings per share are −26.14.

Across the 4 fiscal years on file, revenue moves from $34.22M in 2022 to $622.49K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 6.21. On price-to-sales that is 145.6% above the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Over the trailing twelve months the total return is −93.69%. Across 5 years the annualized return works out at −69.79%. The reported beta is 2.9. Annualized volatility over the trailing 9 years is 171.87%.

Growth & Income

No dividend is on file for CODX.

The strongest complete calendar year on file is 2020 at +939.11%; the weakest is 2025 at −77.47%. Of the 8 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −87.34% year to date.

Peer Comparison

Co-Diagnostics, Inc. Common Stock (CODX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Co-Diagnostics, Inc. Common Stock CODX $4.48M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Co-Diagnostics, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Co-Diagnostics, Inc. Common Stock

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Visit website →